Barrett's esophagus: Environmental influences in the progression of dysplasia

World Journal of Surgery

Volumn 27, Issue 9, 2003, Pages 1014-1017

  Boulton, Ralph A ^a   Usselmann, Bernhard ^a   Mohammed, Imtiyaz ^a   Jankowski, Janusz ^a  

^a UNIVERSITY OF LEICESTER   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

BILE ACID; DEOXYCHOLIC ACID; DNA; OMEPRAZOLE; PROTEIN P53; PROTON PUMP INHIBITOR;

ADAPTATION; ADENOCARCINOMA; ARTICLE; BARRETT ESOPHAGUS; CANCER RISK; DISEASE ASSOCIATION; DISEASE COURSE; DNA DAMAGE; DYSPLASIA; ENVIRONMENTAL FACTOR; EPITHELIUM CELL; ESOPHAGUS; ESOPHAGUS CARCINOMA; ESOPHAGUS MUCOSA; ESOPHAGUS TUMOR; GASTROINTESTINAL ENDOSCOPY; GENE MUTATION; GENOME IMPRINTING; HUMAN; INTESTINE METAPLASIA; METAPLASIA; PATHOLOGY; PATHOPHYSIOLOGY; PHYSIOLOGY; PRECANCER; TUMOR SUPPRESSOR GENE;

ADAPTATION, PHYSIOLOGICAL; BARRETT ESOPHAGUS; BILE ACIDS AND SALTS; EPITHELIAL CELLS; ESOPHAGEAL NEOPLASMS; ESOPHAGUS; HUMANS; METAPLASIA; PRECANCEROUS CONDITIONS;

EID: 0141430893     PISSN: 03642313     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00268-003-7054-0     Document Type: Article

References (47)

1. Naef AP, Savary M, Ozzello L. Columnar-lined lower esophagus; an acquired lesion with malignant predisposition: report on 140 cases of Barrett's esophagus with adenocarcinomas. J. Thorac. Cardiovasc. Surg. 1975;70:826-835
2. Cameron AJ, Ott BJ, Payne WS. The incidence of adenocarcinoma in columnar-lined (Barrett's) esophagus. N Eng J Med 1985;313:857-859
3. Cameron AJ. Epidemiology of columnar-lined esophagus and adenocarcinoma. Gastroenterol. Clin. North Am. 1997;26:487-494
4. Devesa SS, Blot WJ, Fraumeni JF. Changing patterns in the incidence of esophageal and gastric carcinoma in the United States. Cancer 1998;83:2049-2053
5. Shaheen NJ, Crosby MA, Bozymski EM, et al. Is there publication bias in the reporting of cancer risk in Barrett's oesophagus? Gastroenterology 2000;119:333-338
6. Sharma P, Morales TG, Bhattacharya A, et al. Dysplasia in short-segment Barrett's esophagus: a prospective 3-year follow-up. Am. J. Gastroenterol. 1997;92:2012-2016
7. Nandurkar S, Talley NJ, Martin CJ, et al. Short segment Barrett's oesophagus: prevalence, diagnosis and associations. Gut 1997;40:710-715
8. Spechler SJ, Zeroogian JM, Antonioli DA, et al. Prevalence of metaplasia at the gastro-oesophageal junction. Lancet 1994;344:1533-1536
9. Donahue D, Navab F. Significance of short-segment Barrett's esophagus. J. Clin. Gastroenterol. 1997;25:480-484
10. Richter JE. Intestinal metaplasia and the squamocolumnar junction: what does it all mean? Gut 1998;42:604-605
11. Haggitt RC. Barrett's Esophagus, dysplasia and adenocarcinoma. Hum. Pathol. 1994;25:982-993
12. Sarr MG, Hamilton SR, Marrone GC, et al. Barrett's esophagus: its prevalence and association with adenocarcinoma in patients with symptoms of gastroesophageal reflux. Am. J. Surg. 1985;149:187-193
13. Winter C, Spurling TJ, Chobanian SJ, et al. Barrett's esophagus: a prevalent, occult complication of gastroesophageal reflux disease. Gastroenterology 1987;92:118-124
14. Chalasani N, Wo JM, Waring JP. Racial differences in the histology, location, and risk factors of esophageal cancer. J. Clin. Gastroenterol. 1998;26:11-13
15. Cameron AJ. Epidemiologic studies and the development of Barrett's Esophagus. Endoscopy 1993;25:635-636
16. Cameron AJ, Zinmeister AR, Ballard DJ, et al. Prevalence of columnar-lined (Barrett's) esophagus: comparison of population-based clinical and autopsy findings. Gastroenterology 1990;99:918-922
17. Gillen P, Keeling P, Byrne PJ, et al. Experimental columnar metaplasia in canine oesophagus. Br. J. Surg. 1988;75:113-115
18. Jankowski J, Coghill G, Murphy S, et al. Epidermal growth factor receptors in the oesophagus. Gut 1992;33:439-443
19. Jankowski J, Austin W, Howat K, et al. Proliferating cell nuclear antigen labelling in the oesophagus; correlation with autoradiography. Eur. J. Gastroenterol. Hepatol. 1992;4:579-584
20. Pera M, Casdesa A, Bombi JA, et al. Influence of esophagojejunostomy on the induction of adenocarcinoma of the distal esophagus in Sprague-Dawley rats by subcutaneous injection of 2,6-dimethylnitrosomorpholine. Cancer Res. 1989;49:6803-6808
21. Spechler SJ. Barrett's esophagus. Semin. Oncol. 1994;21:431-437
22. Jankowski JA, Wright NA, Meltzer SJ, et al. Molecular evolution of the metaplasia-dysplasia-adenocarcinoma sequence in the esophagus. Am. J. Pathol. 1999;154:965-973
23. Mendes de Almeida JC, Chaves P, Pereira AD, et al. Is Barrett's esophagus the precursor of most adenocarcinomas of the esophagus and cardia? A biochemical study. Ann. Surg. 1997;226:725-733
24. Potet F, Flejou JF, Gervaz H, et al. Adenocarcinoma of the lower oesophagus and the esophagogastric junction. Semin. Diagn. Pathol. 1991;8:126-136
25. Altorki NK, Sunagawa M, Little AG, et al. High-grade dysplasia in the columnar-lined esophagus. Am. J. Surg. 1991;161:97-99
26. Levine DS, Haggitt RC, Blount PL, et al. An endoscopic biopsy protocol can differentiate high-grade dysplasia from early adenocarcinoma in Barrett's esophagus. Gastroenterology 1995;105:40-50
27. Reid BJ, Haggitt RC, Rubin CE, et al. Barrett's esophagus: Correlation between flow-cytometry and histology in detection of patients at risk for adenocarcinoma. Gastroenterology 1987;93:1-11
28. Haggitt RC, Reid BJ, Rabinovitch PS, et al. Barrett's esophagus: correlation between mucin histochemistry, flow cytometry, and histologic diagnosis for predicting increased cancer risk. Am. J. Pathol. 1988;131:53-61
29. Blount PL, Meltzer SJ, Yin J, et al. Clonal ordering of 17p and 5q allelic losses in Barrett's dysplasia and adenocarcinoma. Proc. Natl. Acad. Sci. U. S. A. 1993;90:3221-3225
30. Blount PL, Galipeau PC, Sanchez CA, et al. 17p allelic losses in diploid cells of patients with Barrett's esophagus who develop aneuploidy. Cancer Res. 1994;54:2292-2295
31. Gore S, Healey CJ, Sutton R, et al. Regression of columnar lined (Barrett's) oesophagus with continuous omeprazole therapy. Aliment. Pharmacol. Ther. 1993;7:623-628
32. Sharma P, Sampliner RE, Camargo E. Normalization of esophageal pH with high-dose proton pump inhibitor therapy does not result in regression of Barrett's esophagus. Am. J. Gastroenterol. 1997;92:582-585
33. Brand DL, Ylvisaker JT, Gelfand M, et al. Regression of columnar-lined esophageal (Barrett's) epithelium after anti-reflux surgery. N. Engl. J. Med. 1980;302:844-848
34. Sagar PM, Ackroyd R, Hosie KB, et al. Regression and progression of Barrett's oesophagus after anti-reflux surgery. Br. J. Surg. 1995;82:806-810
35. Fennerty MB, Corless CL, Sheppard B, et al. Pathological documentation of complete elimination of Barrett's metaplasia following endoscopic multipolar electrocoagulation therapy. Gut 2001;49:142-144
36. Tselepis C, Perry I, Dawson C, et al. Tumour necrosis factor-alpha in Barrett's oesophagus: a potential novel mechanism of action. Oncogene 2002;21:6071-6081
37. Attwood SEA, DeMeester TR, Bremmer CG, et al. Alkaline gastroesophageal reflux: mplications in the development of complications in Barrett's columnar-lined lower esophagus. Surgery 1989;106:764-770
38. Menges M, Müller M, Zeitz M. Increased acid and bile reflux in Barrett's esophagus compared to reflux esophagitis, and effect of proton pump inhibitor therapy. Am. J. Gastroenterol. 2001;96:331-337
39. Fiorucci S, Santucci L, Chiucchiu S, et al. Gastric acidity and gastroesophageal reflux patterns in patients with esophagitis. Gastroenterology 1992;103:855-861
40. Kauer WK, Peters JH, DeMeester TR, et al. Mixed reflux of gastric and duodenal juices is more harmful to the oesophagus than gastric juice alone: the need for surgical therapy re-emphasised. Ann. Surg. 1995;222:525-531
41. Vaezi MF, Richter JE. Role of duodenogastroesophageal reflux in gastroesophageal reflux disease. Gastroenterology 1996;111:1192-1199
42. Nehra D, Howell P, Williams CP, et al. Toxic bile acids in gastrooesophageal reflux disease: influence of gastric acidity. Gut 1999;44:598-602
43. Nagengast FM, Grubben MJ, van Munster IP. Role of bile acids in colorectal carcinogenesis. Eur. J. Cancer 1995;31A:1067-1070
44. Garewal H, Bernstein H, Bernstein C, et al. Reduced bile acid-induced apoptosis in "normal" colorectal mucosa: a potential biological marker for cancer risk. Cancer Res. 1996;56:1480-1483
45. Katada N, Hinder RA, Smyrk TC, et al. Apoptosis is inhibited early in the dysplasia-carcinoma-sequence of Barrett's esophagus. Arch. Surg. 1997;132:728-733
46. Hughes SJ, Nambu Y, Soldes OS, et al. Fas/APO-1 (CD95) is not translocated to the cell membrane in esophageal adenocarcinoma. Cancer Res. 1997;57:5571-5578
47. Tselepis C, Perry I, Boulton R, et al. Endogenous secondary bile acid levels modify epithelial biology in Barrett's oesophagus. Mol. Pathol. (in press)